Strategy for determination of an efficient Cochleate particle size.
Cochleate structures obtained from the outer membrane of Neisseria meningitidis serotype B have demonstrated to be high immunogenicity when administrated by intramuscular, oral or intranasal routes, and could be used as adjuvant and meningococcal nasal vaccine candidate. Due to the microparticulate nature of Cochleate it is necessary to control the particle size since it capture by cells of the immune system could be affected by this aspect. We combined optic microscopy and immunisation experiments to select the optimum particle size. Six different processes of producing Cochleate obtaining were evaluated and different mechanical stress conditions were carried out to homogenize and modulate the particles size. The more immunogenic particles were selected on the basis of the levels of specific IgA and IgG antibodies induced after intranasal immunisation in mice. The best treatment parameter for mechanical stress of the Cochleate was prolonged treatment with untrasonic low frequency waves.
Gil
Danay
D
Immunology Department, Finlay Institute, P.O. Box 16017, Havana, Cuba. dgil@finlay.edu.cu
Bracho
Gustavo
G
Zayas
Caridad
C
del Campo
Judith
J
Acevedo
Reinaldo
R
Toledo
Arturo
A
Lastre
Miriam
M
Pérez
Oliver
O
D000276:Adjuvants, Immunologic / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology; D000818:Animals; D022401:Meningococcal Vaccines / Q000737:chemistry* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008853:Microscopy; D038541:Neisseria meningitidis, Serogroup B / Q000737:chemistry; D010316:Particle Size; D011510:Proteolipids / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D022401:Meningococcal Vaccines; D011510:Proteolipids; C020485:proteoliposomes